The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.

BMC Cancer · 2024 · PMC11340044 · PMID 39174912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The systemic inflammation scores, including NLR, LLR, and PLR, showed a decreasing trend after RFA compared with values before RFA, which is related to the increase in peripheral blood lymphocyte count following radiofrequency ablation.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.